PMC:7299399 / 22587-23282 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T80","span":{"begin":23,"end":31},"obj":"Disease"}],"attributes":[{"id":"A80","pred":"mondo_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"ored in the context of SARS-CoV-2.27 An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). A third aluminum salt (alum) adjuvanted inactivated vaccine, developed by Beijing-based Sinovac Biotech’s, was able to provide partial or complete protection in rhesus macaques, according to a recent article published in Science,71 and is currently being tested in Phase"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T226","span":{"begin":205,"end":211},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T227","span":{"begin":215,"end":216},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T228","span":{"begin":258,"end":259},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T229","span":{"begin":356,"end":359},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T230","span":{"begin":397,"end":404},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T231","span":{"begin":425,"end":426},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T232","span":{"begin":586,"end":601},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9544"},{"id":"T233","span":{"begin":616,"end":617},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T234","span":{"begin":654,"end":656},"obj":"http://purl.obolibrary.org/obo/CLO_0054055"},{"id":"T235","span":{"begin":680,"end":686},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"ored in the context of SARS-CoV-2.27 An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). A third aluminum salt (alum) adjuvanted inactivated vaccine, developed by Beijing-based Sinovac Biotech’s, was able to provide partial or complete protection in rhesus macaques, according to a recent article published in Science,71 and is currently being tested in Phase"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T140","span":{"begin":225,"end":227},"obj":"Chemical"},{"id":"T141","span":{"begin":433,"end":441},"obj":"Chemical"},{"id":"T142","span":{"begin":442,"end":446},"obj":"Chemical"},{"id":"T144","span":{"begin":448,"end":452},"obj":"Chemical"}],"attributes":[{"id":"A140","pred":"chebi_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A141","pred":"chebi_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/CHEBI_28984"},{"id":"A142","pred":"chebi_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/CHEBI_24866"},{"id":"A143","pred":"chebi_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/CHEBI_26710"},{"id":"A144","pred":"chebi_id","subj":"T144","obj":"http://purl.obolibrary.org/obo/CHEBI_74768"}],"text":"ored in the context of SARS-CoV-2.27 An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). A third aluminum salt (alum) adjuvanted inactivated vaccine, developed by Beijing-based Sinovac Biotech’s, was able to provide partial or complete protection in rhesus macaques, according to a recent article published in Science,71 and is currently being tested in Phase"}

{"project":"LitCovid-PubTator","denotations":[{"id":"336","span":{"begin":217,"end":227},"obj":"Gene"},{"id":"337","span":{"begin":23,"end":33},"obj":"Species"},{"id":"338","span":{"begin":586,"end":601},"obj":"Species"},{"id":"339","span":{"begin":433,"end":446},"obj":"Chemical"},{"id":"340","span":{"begin":448,"end":452},"obj":"Chemical"}],"attributes":[{"id":"A337","pred":"tao:has_database_id","subj":"337","obj":"Tax:2697049"},{"id":"A338","pred":"tao:has_database_id","subj":"338","obj":"Tax:9544"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ored in the context of SARS-CoV-2.27 An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). A third aluminum salt (alum) adjuvanted inactivated vaccine, developed by Beijing-based Sinovac Biotech’s, was able to provide partial or complete protection in rhesus macaques, according to a recent article published in Science,71 and is currently being tested in Phase"}

{"project":"2_test","denotations":[{"id":"32519842-32259480-158493","span":{"begin":34,"end":36},"obj":"32259480"},{"id":"32519842-32376603-158494","span":{"begin":654,"end":656},"obj":"32376603"}],"text":"ored in the context of SARS-CoV-2.27 An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). A third aluminum salt (alum) adjuvanted inactivated vaccine, developed by Beijing-based Sinovac Biotech’s, was able to provide partial or complete protection in rhesus macaques, according to a recent article published in Science,71 and is currently being tested in Phase"}